Characteristic | Time to death (N = 100) | Neurological sequelae or death (N = 96) | ||||
---|---|---|---|---|---|---|
Death/No at risk | HR (95Â % CI) | P | Events/No at risk | OR (95Â % CI) | P | |
Sex | ||||||
 aMale | 10/56 (17.9 %) | 0.61 | 0.36 | 23/54 (42.6 %) | 1.11 | 0.80 |
 Female | 5/44 (11.4 %) | (0.21–1.78) |  | 19/42 (45.2 %) | (0.49–2.52) |  |
Age | ||||||
 a<5 years | 11/67 (16.5 %) | 0.70 | 0.54 | 30/64 (46.9 %) | 0.68 | 0.38 |
  ≥ 5 years | 4/33 (12.1 %) | (0.22–2.20) |  | 12/32 (37.5 %) | (0.28–1.61) |  |
Duration of symptoms N = 89 | 1.00 | 0.4 | – | 1.01 | 0.43 | |
(per +1 day) |  | (0.98–1.01) |  |  | (0.98–1.04) |  |
Neck stiffness | ||||||
 aNo | 1/25 (4.0 %) | 5.15 | 0.11 | 5/24 (20.8 %) | 4.02 | 0.01 |
 Yes | 14/75 (18.7 %) | (0.68–39.16) |  | 37/72 (51.4 %) | (1.44–13.18) |  |
HIV co-infection | ||||||
 aNo | 13/92 (14.1 %) | 1.85 | 0.55 | 39/88 (44.3 %) | 0.42 | 0.43 |
 Yes | 1/4 (25.0 %) | (0.24–14.17) |  | 1/4 (25.0 %) | (0.02–3.42) |  |
BCS Grade | ||||||
age <5Â years | ||||||
 aBI | 0/43 (0 %) | 1.00 | <0.001 | 10/40 (25.0 %) | 1.00 | <0.001 |
 BII | 3/12 (25.0 %) | 27.96 b |  | 9/12 (75.0 %) | 9.00 |  |
 |  | (2.71–3760) |  |  | (2.21–47.06) |  |
 BIII | 8/12 (67.0 %) | 94.64 b |  | 11/12 (91.7 %) | 33.00 |  |
 |  | (11.71–12,260) |  |  | (5.44–643.12) |  |
TBM grade | ||||||
(age ≥ 5 years) | ||||||
 aI | 1/16 (6.3 %) | 1.00 | 0.28 | 2/15 (13.3 %) | 1.00 | 0.01 |
 II | 1/11 (9.1 %) | 1.41 |  | 5/11 (45.5 %) | 5.41 |  |
 |  | (0.09–22.5) |  |  | (0.81–36) |  |
 III | 2/6 (33.3 %) | 6.26 |  | 5/6 (83.3 %) | 32.5 |  |
 |  | (0.57–69.2) |  |  | (2.4–443) |  |
Convulsions | ||||||
 aNo | 5/61 (8.2 %) | 3.46 | 0.02 | 20/59 (33.9 %) | 2.86 | 0.01 |
 Yes | 10/39 (25.6 %) | (1.18–10.13) |  | 22/37 (59.5 %) | (1.24–6.81) |  |
Decreased level of consciousness | ||||||
 aNo | 1/58 (1.7 %) | 22.9 | <0.001 | 10/54 (18.5 %) | 14.08 | <0.001 |
 Yes | 14/42 (33.3 %) | (3.01–174.3) |  | 32/42 (76.2 %) | (5.46–39.85) |  |
Focal neurological deficits | ||||||
 aNo | 0/53 (0 %) | 15.66 | 0.01 | 6/50 (12.0 %) | 15.4 | <0.001 |
 Yes | 4/32 (12.5 %) | (1.67–2075) |  | 21/31 (67.7 %) | (5.22–51.96) |  |
Extra meningeal TB | ||||||
 aNo | 6/51 (11.8 %) | 2.3 | 0.11 | 19/57 (33.3 %) | 2.87 | 0.01 |
 Yes | 9/30 (30.0 %) | (0.82–6.45) |  | 23/39 (59.0 %) | (1.25–6.80) |  |
TB culture | ||||||
 aNegative | 2/14 (14.3 %) | 2.72 | 0.33 | 4/16 (25.0 %) | 4.50 | 0.16 |
 Positive | 2/3 (66.7 %) | (0.38–19.4) |  | 3/5 (60.0 %) | (0.56–45.4) |  |
Hydrocephalusc | ||||||
 aNo | 2/31 (6.5 %) | 3.46 | 0.10 | 6/31 (19.4 %) | 9.72 | <0.001 |
 Yes | 6/30 (20.0 %) | (0.70–17.16) |  | 21/30 (70.0 %) | (2.97–32) |  |
Cranial nerve palsy | ||||||
 No | 14/70 (20.0 %) | 5.42 | 0.10 | 29/70 (41.4 %) | 0.71 | 0.45 |
 Yes | 1/26 (3.8 %) | (0.71–42.2) |  | 13/26 (50.0 %) | (0.29–1.75) |  |
CSF Protein | N = 99 | 1.74 | 0.002 | N = 94 | 1.65 | 0.01 |
(per + 1 g/L) |  | (1.22–2.49) |  |  | (1.14–2.51) |  |
CSF Lactate | N = 77 | 1.14 | 0.04 | N = 73 | 1.20 | 0.03 |
(per + 1 mmol/L) |  | (1.01–1.29) |  |  | (1.01–1.47) |  |
CSF Glucose | N = 100 | 0.45 | 0.05 | N = 96 | 0.65 | 0.10 |
(per + 1 mmol/L) |  | (0.20–0.98) |  |  | (0.38–1.08) |  |